Revenue Breakdown
Composition ()
No data
Revenue Streams
ANI Pharmaceuticals Inc (ANIP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sales of Cortrophin Gel, accounting for 44.7% of total sales, equivalent to $101.85M. Other significant revenue streams include Generic pharmaceutical products and Sales of ILUVIEN and YUTIQ. Understanding this composition is critical for investors evaluating how ANIP navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, ANI Pharmaceuticals Inc maintains a gross margin of 50.26%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.79%, while the net margin is 13.09%. These profitability ratios, combined with a Return on Equity (ROE) of 16.34%, provide a clear picture of how effectively ANIP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ANIP competes directly with industry leaders such as NVAX and NRIX. With a market capitalization of $1.69B, it holds a leading position in the sector. When comparing efficiency, ANIP's gross margin of 50.26% stands against NVAX's 84.98% and NRIX's 100.00%. Such benchmarking helps identify whether ANI Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
